Menu Close
The Conversation

Michael Dobbie

1

Article

1

Comment
Chief Executive Officer, Phenomics Australia, Australian National University

Over the last 15 years, I have led national scientific programs gaining broad experience in the management of scientific business, biomedical research project design, Federal government agreements, funding and policy. I draw upon an extensive network of scientific and governmental partners and colleagues, to enable and govern collaborations on a national scale.

Since, 2015 I have been the CEO of Phenomics Australia, an Australian government funded partnership that provides services to support the discovery of genetic causes of disease. This is achieved through the creation, characterisation and curation of new models of human disease. With the completion of the sequencing of the human genome, I am involved in enabling researchers to discover what the genes do, and the biological consequences of faulty genes. I currently promote the application of functional genomics and phenomics approaches towards the better understanding of disease.

Prior to these scientific business management endeavours, I was a biomedical researcher with a PhD in neurochemistry from the University of London. Over 20 years I contributed to original research in fields including genetics, vascular biology, cancer angiogenesis, neuroscience, metabolism, developmental biology, malaria, and oxidative stress.

Experience

  • 2013–present
    Chief Executive Officer, Australian Phenomics Network, The Australian National University
  • 2014–present
    Manager, National Centre for Indigenous Genomics, The Australian National University
  • 2006–2014
    Scientific Business Manager, Australian Phenomics Facility, The Australian National University
  • 2012–2013
    Chief Operating Officer, Australian Phenomics Network, The Australian National University
  • 2003–2006
    Postdoctoral Translational Research Fellow, Cancer Research UK

Education

  • 2001 
    University of London, PhD
  • 1994 
    University of Sydney, MSc
  • 1985 
    University of Technology, Sydney, BAppSc (Biomed Sc)

Publications

  • 2013
    Genome-Wide ENU Mutagenesis in Combination with High Density SNP Analysis and Exome Sequencing Provides Rapid Identification of Novel Mouse Models of Developmental Disease, PLoS One
  • 2011
    ENU Mutagenesis Screen to Establish Motor Phenotypes in Wild-Type Mice and Modifiers of a Pre-Existing Motor Phenotype in Tau Mutant Mice, Journal of Biomedicine and Biotechnology
  • 2006
    Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer, Clinical Cancer Research
  • 2003
    Nitric oxide and peroxynitrite cause irreversible increases in the K(m) for oxygen of mitochondrial cytochrome oxidase: in vitro and in vivo studies, Biochim Biophy Acta
  • 2003
    Interaction between flavonoids and the blood-brain barrier: in vitro studies, Journal of Neurochemistry
  • 2002
    Drug resistance in epilepsy: the role of the blood-brain barrier, Novartis Foundation Symposiums
  • 2001
    A comparison of the induction of immortalized endothelial cell impermeability by astrocytes, Neuroreport
  • 1999
    Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-alpha in an in vitro model of the blood-brain barrier, Brain Research
  • 1998
    An immortalized in vitro model of the blood-brain barrier: glutathione levels and sensitivity to oxidative stress, Biochemical Society Transactions
  • 1998
    Decreased endothelial cell glutathione and increased sensitivity to oxidative stress in an in vitro blood-brain barrier model system, Brain Research
  • 1997
    Concentrations of quinolinic acid in cerebrospinal fluid measured by gas chromatography and electron-impact ionisation mass spectrometry. Age-related changes in a paediatric reference population, Journal of Chromatography Part B Biomedical Science Applications
  • 1996
    Renal and spermatozoal toxicity of alpha-bromohydrin, 3-bromolactate and 3-bromopyruvate, Journal of Applied Toxicology
  • 1991
    The male antifertility activity of 6-chloro-6-deoxyglucose, Contraception
  • 1988
    Is the nephrotoxicity of (R)-3-chlorolactate in the rat caused by 3-chloropyruvate?, Xenobiotica

Professional Memberships

  • Australia and New Zealand Society for Cell and Developmental Biology

Research Areas

  • Medical And Health Sciences (11)
  • Genetics (0604)
  • Genomics (060408)
  • Medical Genetics (Excl. Cancer Genetics) (110311)
  • Cancer Genetics (111203)